Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

896
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
896
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.9K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Higher Mental Functions of Brain: Learning and Memory01:26

Higher Mental Functions of Brain: Learning and Memory

2.3K
Memory is one of the most vital higher mental functions of the brain. Memory is closely related to learning because it enables us to retain information and experiences from our past to use them in our present life. It also helps us to remember facts, events, and skills, such as riding a bike or swimming. There are two types of memory — declarative memory, which involves memorizing facts or events, and procedural memory, which enables us to remember how to do something like writing or...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Long-term Depression01:03

Long-term Depression

3.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From wild to domestic and in between: how domestication and feralization changed the morphology of rabbits.

Proceedings. Biological sciences·2025
Same author

Treating Alzheimer's Disease: Focusing on Neurodegenerative Consequences.

Journal of Alzheimer's disease : JAD·2024
Same author

Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration.

Trends in pharmacological sciences·2024
Same author

Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.

Journal of Alzheimer's disease : JAD·2023
Same author

The ε-Isozyme of Protein Kinase C (PKCε) Is Impaired in ALS Motor Cortex and Its Pulse Activation by Bryostatin-1 Produces Long Term Survival in Degenerating SOD1-G93A Motor Neuron-like Cells.

International journal of molecular sciences·2023
Same author

Sting and p53 DNA repair pathways are compromised in Alzheimer's disease.

Scientific reports·2023

Related Experiment Video

Updated: Apr 12, 2026

Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

16.3K

Towards universal therapeutics for memory disorders.

Miao-Kun Sun1, Thomas J Nelson1, Daniel L Alkon1

  • 1Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, Morgantown, WV 26505, USA.

Trends in Pharmacological Sciences
|May 12, 2015
PubMed
Summary
This summary is machine-generated.

Many memory disorders share synaptic pathology. Therapeutics targeting synaptic function, like protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF), offer universal treatment value for memory impairments.

Keywords:
brain-derived neurotrophic factorlearning and memorymemory disorderspost-traumatic stress disorderprotein kinase Cstem cell

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

24.2K

Related Experiment Videos

Last Updated: Apr 12, 2026

Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

16.3K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

24.2K

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Memory disorders stem from diverse causes like neurodegeneration, TBI, and vascular disease.
  • Structural and functional synaptic deficits are a common pathological hallmark across various memory impairments.
  • Synaptic dysfunction represents a critical convergence point in the pathophysiology of memory disorders.

Purpose of the Study:

  • To highlight the shared synaptic pathology in memory disorders.
  • To explore the therapeutic potential of targeting synaptic function for broad applicability.
  • To identify key molecular pathways, including protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF), for memory therapeutics.

Main Methods:

  • Review of accumulating evidence on memory disorder pathology.
  • Analysis of commonalities in structural and functional synaptic deficits.
  • Identification of synaptogenic molecular cascades as therapeutic targets.

Main Results:

  • Synaptic deficits are a core, convergent feature in numerous memory disorders.
  • Targeting synaptic loss and dysfunction offers universal therapeutic potential.
  • Protein kinase C (PKC) and brain-derived neurotrophic factor (BDNF) pathways are key targets for synaptogenesis.

Conclusions:

  • Therapeutics focused on synaptic repair and function hold promise for diverse memory disorders.
  • Interventions targeting PKC and BDNF may slow, halt, or reverse memory disorder progression at the synaptic level.
  • These synaptic therapeutics can be used alone or as adjuncts to existing treatments for memory disorders.